Congress Abstracts
- (Levrat-Guillen et al., EPV172 / #635). This retrospective cohort analysis showed that adults with type 1 diabetes in Sweden reported fewer severe hypoglycemia episodes after switching from real-time continuous glucose monitoring with predictive alarms to intermittently scanned CGM.
- (Ratzki-Leewing et al, OP050 / #212). Real-world evidence from Ontario demonstrated that in individuals over 65 years old with type 2 diabetes receiving GLP-1 receptor agonists and/or oral therapy, initiation of Freestyle Libre was associated with a significant reduction in HbA1c, while statistically significant improvements in healthcare resource utilization were observed only among those on oral therapy, possibly due to the smaller number of GLP-1 RA users in the study.
- (Huang & Bindal, EPV202 / #720). This retrospective matched-cohort (CGM users vs no CGM) showed that consistent use of FreeStyle Libre continuous glucose monitoring is associated with significantly lower rates of GLP-1 receptor agonist discontinuation among adults with type 2 diabetes on non-intensive therapy, suggesting improved medication adherence.
- (Soriano et al., EPV216 / #1303). This randomized controlled trial found that adults with type 2 diabetes (T2D) using FreeStyle Libre 3 showed significantly greater improvements in HbA1c and T2D engagement scores compared to those using traditional blood glucose monitoring.
- (Bergenstal et al., 165-OR). This prospective cohort study found that the updated GMI (uGMI) aligns more accurately with lab-measured A1C than the original formula, improving CGM interpretation across populations.
- (Ajjan et al., 167-OR). This retrospective cohort study showed that personalized A1C (pA1C), adjusted for individual differences in red blood cell lifespan and glucose uptake, improves correlation with GMI and may better reflect glycemic exposure.
- (Naqvi et al., 157-OR). This secondary analysis of a randomized controlled trial in adults with T2D, showed that higher engagement in a digital diabetes self-management and education support (DSMES) + CGM program led to greater HbA1c reduction and improved time in range, supporting the value of integrated digital solutions.
- (Tillman et al., 1000-P). This prospective real-world study found that use of the Bigfoot Unity System resulted in sustained HbA1c improvement, reduced diabetes distress, and increased hypoglycemia confidence over 12 months in adults with T2D on multiple daily injections of insulin
- (Singh et al., 989-P). This retrospective real-world analysis found that minimum glucose of the day (MGD), assessed by CGM, often occurred outside fasting hours in patients with T2D on long-acting insulin. These data suggest that CGM may provide a tool for identifying MGD, which may be used to titrate long-acting insulin.
- (Polonsky et al., LB-5472). This qualitative interview study explored how Freestyle Libre 3 sensor use improved awareness, decision-making, and self-efficacy in people with T2D, driving healthier behaviors.
- (Smith-Levitin et al., 1008-P). This survey study showed that OB-GYNs recognize benefits of CGM use in pregnancy care but face barriers like data interpretation and insurance access, highlighting the need for education and support.
- (Munshi et al., 1062-P). This budget impact model found that expanding CGM access to Medicare participants with T2D not on insulin could save $331 per person annually, with significant reductions in overall healthcare costs.
- (Rowes et al., 1068-P). This budget impact model showed that CGM coverage for patients with uncontrolled T2D in US-based commercial plans could save $1.3B over 3 years, driven by reduced hospitalizations and emergency visits.
- (Ajjan et al.) This 26-week prospective observational study validated an updated GMI (uGMI) and personalized A1C (pA1C), showing that uGMI improved alignment with HbA1c, while pA1C further enhanced correlation by accounting for individual red blood cell differences - especially in T2D populations not routinely using CGM.
- (Quadri et al.) This retrospective real-world analysis of over 3 million ketone tests found that most were performed when glucose was ≥250 mg/dL, aligning with clinical guidance. However, elevated ketones can occur at lower glucose levels, suggesting a need for more accessible and proactive ketone monitoring.
- (Wright et al.) This Medicaid-focused budget impact model projected $1.9B in savings over 3 years by expanding CGM coverage to all patients with T2D, including those not on insulin, primarily through reduced hospitalizations and ER visits.
- (Riveline et al.) This retrospective cross-sectional study found that people with T2D in France face significantly higher rates of vascular complications than non-diabetic controls. Despite new therapies and technologies, treatment patterns remain largely unchanged since 2013, highlighting persistent treatment inertia and underuse of CGM.
- (Riveline et al.) This retrospective cohort study of 2,685 people with T1D found a 4.5% prevalence of DKA, with higher risk linked to younger age at diagnosis, shorter disease duration, lower BMI, and higher HbA1c. DKA was also associated with increased severe hypoglycemia, highlighting the need for individualized, continuous glucose and ketone monitoring.
CE/CME Programs
- Supporting Healthy Eating Habits through Continuous Glucose Monitors (CGMs)
- Taking a Personalized Approach to Diabetes Management With iCGM: A Look at Advancing Technology, Data Comprehension, and the Pharmacist's Role
- 2024 PTCE Diabetes Day of Education: Best Practices for Optimizing Integrated Continuous Glucose Monitoring
- Integrating and applying CGM technology for improved primary care management of type 2 diabetes
- Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered by Patients™ Interview
stay connected